New analysis shows survival benefit of Novartis’ Kisqali
In patients with liver metastases, Kisqali combination therapy cut the risk of death by 47% and 37% in two trials
Read More
Tag: MONALEESA
Kisqali wins speedy US breast cancer nod
Novartis’ Kisqali has been approved for breast cancer in the US less than one month after being filed with the US Food and Drug Administration.
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
